115 related articles for article (PubMed ID: 22171588)
1. Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature.
Elmer J; Wittels KA
Transfus Med; 2012 Apr; 22(2):108-15. PubMed ID: 22171588
[TBL] [Abstract][Full Text] [Related]
2. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
3. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
Lee FM; Chan AK; Lau KK; Chan HH
Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.
Vavra KA; Lutz MF; Smythe MA
Ann Pharmacother; 2010 Apr; 44(4):718-26. PubMed ID: 20233918
[TBL] [Abstract][Full Text] [Related]
5. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
Le Roux P; Pollack CV; Milan M; Schaefer A
J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
[TBL] [Abstract][Full Text] [Related]
6. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
Perzborn E; Gruber A; Tinel H; Marzec UM; Buetehorn U; Buchmueller A; Heitmeier S; Laux V
Thromb Haemost; 2013 Jul; 110(1):162-72. PubMed ID: 23636219
[TBL] [Abstract][Full Text] [Related]
7. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
Dickneite G
Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
[TBL] [Abstract][Full Text] [Related]
9. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor.
Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
Thromb J; 2017; 15():6. PubMed ID: 28239301
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
11. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.
Zhou ZY; Hay JW
Clin Ther; 2012 Feb; 34(2):434-45. PubMed ID: 22285208
[TBL] [Abstract][Full Text] [Related]
13. Use of recombinant factor VIIa for emergency reversal of anticoagulation.
Ingerslev J; Vanek T; Culic S
J Postgrad Med; 2007; 53(1):17-22. PubMed ID: 17244965
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study of rFVIIa, 4-factor PCC, and a rFVIIa and 3-factor PCC combination in improving bleeding outcomes in the warfarin and non-warfarin patient.
DeLoughery E; Avery B; DeLoughery TG
Am J Hematol; 2016 Jul; 91(7):705-8. PubMed ID: 27074566
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors.
Knight C; Danø AM; Kennedy-Martin T
Adv Ther; 2009 Jan; 26(1):68-88. PubMed ID: 19156372
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI
Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158
[TBL] [Abstract][Full Text] [Related]
17. Reversing anticoagulant therapy.
Ghanny S; Warkentin TE; Crowther MA
Curr Drug Discov Technol; 2012 Jun; 9(2):143-9. PubMed ID: 22023256
[TBL] [Abstract][Full Text] [Related]
18. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
Res Pract Thromb Haemost; 2017 Jul; 1(1):49-56. PubMed ID: 30046673
[TBL] [Abstract][Full Text] [Related]
19. Current state of knowledge on oral anticoagulant reversal using procoagulant factors.
Nitzki-George D; Wozniak I; Caprini JA
Ann Pharmacother; 2013 Jun; 47(6):841-55. PubMed ID: 23695644
[TBL] [Abstract][Full Text] [Related]
20. Reversal of vitamin K antagonists prior to urgent surgery.
Grobler C; Callum J; McCluskey SA
Can J Anaesth; 2010 May; 57(5):458-67. PubMed ID: 20077167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
